The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be ...
Kinesin-1 is a dynamic heterotetrameric assembly of two heavy and two light chains (KHC and KLC) that mediates microtubule-based intracellular transport of many different cargoes. The complex adopts a ...
Third Quarter 2025 Financial Highlights - Cash Position: Cash and cash equivalents were $81.3 million as of September 30, 2025, compared to $90.4 million as of June 30, 2025. - Revenue: ...
Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025Phase 1b/2 Multiple Ascending Dose ...
These subgroup insights will guide trial design, patient selection, and endpoint strategy for Autonomix's upcoming U.S.-based multicenter clinical study, currently planned to begin in 2026, which will ...
LAS VEGAS, Nov. 4, 2025 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, ...
EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing ...
Allergan Aesthetics, an AbbVie company , today announced it will present data highlighting efficacy, safety and patient-reported outcomes across its portfolio during the 2025 American Society of ...
Starting from the upcoming academic session, the Delhi Directorate of Education (DoE) will enforce a rule that children must be at least six years old to enter Class 1 in both government and private ...
Hosted on MSN
Mixed response for 6+ age norm for Class 1 in Delhi
NEW DELHI: As Delhi prepares to introduce a uniform age of 6+ for admission to Class 1 from the 2026–27 academic session, the announcement has sparked mixed reactions among parents, school ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback